Sermorelin vs Tesamorelin

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicSermorelinTesamorelin
What it is

Growth hormone-releasing factor (human) fragment 1 to 29, amidated, also recorded as groliberin, according to FDA’s substance registry.5

A growth hormone-releasing factor (GHRF) analogue. The label states that it binds to and stimulates human GRF receptors with potency similar to the natural hormone.3

FDA status

Not FDA-approved

FDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness1,2

Not FDA-approved. FDA withdrew the approvals of both Geref applications, NDA 019863 and NDA 020443, effective June 18, 2009, after the maker discontinued them, according to a 2013 Federal Register notice.1,2

Is sermorelin FDA-approved?

FDA-approved

FDA-approved as Egrifta for HIV-associated abdominal fat3,4

FDA-approved. Drugs@FDA lists Egrifta (first approved November 10, 2010), and the label covers reducing excess abdominal fat in adults with HIV and lipodystrophy. The cited label has no boxed warning.3,4

Is tesamorelin FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.6

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Sermorelin is not among them.6,7

Not among the six peptides the policy lists.6

FDA compounding safety-risk page

Not listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list sermorelin, either in category 2 or among withdrawn nominations.8

Not addressed in this profile’s sources.

Kinds of studies cited

Limited human data

  • Small, short, or incompletely reported human study An open-label, multicenter study in 110 previously untreated children with growth hormone deficiency, without a comparison group, reported by the Geref International Study Group (1996).9

Large randomized human trials

  • Large randomized human trial Study 1 (NCT00123253): a randomized, double-blind, placebo-controlled trial in 412 adults with HIV, lipodystrophy and excess abdominal fat, with visceral fat measured by CT scan at 26 weeks.3
  • Large randomized human trial Study 2 (NCT00435136): a randomized, double-blind, placebo-controlled trial of the same design in 404 adults.3
Records collected

0 ClinicalTrials.gov records and 2 PubMed records collected

11 ClinicalTrials.gov records and 21 PubMed records collected

Area of study

Hormones1

Metabolic and weight3

Latest dated events
  1. FDA publishes its determination that Geref was not withdrawn from sale for reasons of safety or effectiveness.1
  2. FDA’s withdrawal of both Geref approvals takes effect, at the maker’s request, according to FDA’s 2013 notice.1
  3. FDA approves Geref for growth hormone deficiency in children, NDA 020443.1,2
  1. DailyMed publishes the Egrifta SV label version cited on this page.3
  2. FDA approves Egrifta, according to Drugs@FDA.4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (March 4, 2013) · FR Doc. 2013-04827 ↗

    Federal Register · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: GEREF (sermorelin acetate), NDA 020443 · original approval September 26, 1997 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    EGRIFTA SV (tesamorelin) kit · SPL version 9 · published 2026-07-31 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  4. 4
    Drugs@FDA application BLA022505 · original submission status AP · 2010-11-10 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Sermorelin substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  8. 8
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  9. 9
    Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group (1996) · PMID 8772599 ↗

    The Journal of Clinical Endocrinology & Metabolism · Official source · Source checked November 15, 2026